Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Macrogenics
(NQ:
MGNX
)
3.290
+0.100 (+3.13%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Macrogenics
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Shareholder Alert: Robbins LLP Informs Investors of the Class Action Filed Against MacroGenics, Inc. (MGNX)
July 30, 2024
From
Robbins LLP
Via
GlobeNewswire
MACROGENICS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against MacroGenics, Inc. and Encourages Investors to Contact the Firm
July 30, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
MACROGENICS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against MacroGenics, Inc. - MGNX
July 30, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
Expert Outlook: Macrogenics Through The Eyes Of 7 Analysts
July 29, 2024
Via
Benzinga
Demystifying Macrogenics: Insights From 14 Analyst Reviews
May 24, 2024
Via
Benzinga
MacroGenics Provides Vobramitamab Duocarmazine Update
July 30, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
MacroGenics Announces Achievement of $100 Million in Milestones Related to Retifanlimab Collaboration with Incyte
July 30, 2024
Confirming cash runway guidance into 2026
From
MacroGenics, Inc.
Via
GlobeNewswire
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of MacroGenics, Inc. (MGNX) Investors
July 30, 2024
From
Kirby McInerney LLP
Via
Business Wire
MGNX INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces That MacroGenics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
July 30, 2024
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
MGNX Investors Have Opportunity to Lead MacroGenics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
July 29, 2024
From
The Schall Law Firm
Via
Business Wire
MACROGENICS, INC. (NASDAQ: MGNX) INVESTOR ALERT: Investors With Large Losses in MacroGenics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
July 29, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Rosen Law Firm Urges MacroGenics, Inc. (NASDAQ: MGNX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
July 29, 2024
From
The Rosen Law Firm, P.A.
Via
Business Wire
DexCom, Zynex, Olin And Other Big Stocks Moving Lower In Friday's Pre-Market Session
July 26, 2024
Via
Benzinga
MacroGenics to Participate in Upcoming Investor Conference
June 11, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
3 Biotech Stocks That Could Be Millionaire-Makers: May Edition
May 25, 2024
Investors should take a close look at these biotech stocks as they position themselves to provide high returns.
Via
InvestorPlace
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
June 03, 2024
Via
Benzinga
MACROGENICS ALERT: Bragar Eagel & Squire, P.C. is Investigating MacroGenics, Inc. on Behalf of MacroGenics Stockholders and Encourages Investors to Contact the Firm
May 14, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against MacroGenics, Inc. (MGNX)
May 13, 2024
From
Kirby McInerney LLP
Via
Business Wire
12 Health Care Stocks Moving In Monday's Intraday Session
May 13, 2024
Via
Benzinga
MacroGenics to Participate in Upcoming Investor Conferences
May 13, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
Masters In Trading - Saturday, May 11
May 11, 2024
In this recap of the most recent trading session, I discuss earnings results and the market rally seen throughout the past week.
Via
Talk Markets
MacroGenics Gets Downgraded Following Disappointing Prostate Cancer Trial Results: 'We Were Surprised By Reported Deaths'
May 10, 2024
Despite MacroGenics' clinical activity, unexpected adverse events raise concerns. Analysts adjust ratings and price targets.
Via
Benzinga
Crude Oil Down 1%; Sweetgreen Shares Spike Higher
May 10, 2024
Via
Benzinga
Exposures
Fossil Fuels
Stocks Pause On Dismal Consumer Confidence; Yields, Dollar Rise As Inflation Expectations Kick Higher, Bitcoin Sinks: What's Driving Markets Friday?
May 10, 2024
A worse-than-expected University of Michigan’s May consumer report halted stock gains on Friday, sparking worries about a potential decline in consumer health amid perceived rising price pressures.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
May 10, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
May 10, 2024
Via
Benzinga
Nasdaq Moves Lower; US Consumer Sentiment Falls In May
May 10, 2024
Via
Benzinga
MacroGenics Shares Tumble After Reporting Adverse Events, Multiple Deaths In Cancer Drug Trial
May 10, 2024
Latest interim data from TAMARACK Phase 2 study by MacroGenics unveils insights into vobramitamab duocarmazine targeting B7-H3 in metastatic prostate cancer. Despite responses, notable safety concerns...
Via
Benzinga
Topics
Death
Exposures
Death
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against MacroGenics, Inc. and Encourages Investors to Contact the Firm
May 10, 2024
From
Schall Law
Via
GlobeNewswire
Dow Jumps Over 100 Points; DNOW Posts Downbeat Earnings
May 10, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.